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BRIEF REPORT: CLINICAL SCIENCE
Identification of Elite and Viremic Controllers From a Large
Urban HIV Ambulatory Center in Kampala, Uganda
Alex Kayongo, MBChB, MSc,* Elena Gonzalo-Gil, PhD,† Emrah Gümüs¸göz, MD,†
Anxious J. Niwaha, MBChB,‡ Fred Semitala, MBChB, MMED, MPH,‡§
Robert Kalyesubula, MBChB, MMED, FISN,§ Bernard S. Bagaya, MSc, PhD,*
Moses L. Joloba, PhD,* and Richard E. Sutton, MD, PhD†
Background: Throughout the world, there are antiretroviral
therapy–naive HIV+ individuals who maintain elevated periph-
eral CD4+ T-cell counts, historically referred to as long-term
nonprogressors (LTNPs). With recent improvements in viral load
(VL) detection methods to levels as low as 20 copies per milliliter,
2 subsets of LTNPs have been deﬁned: elite controllers (ECs),
with undetectable VLs for at least 6–12 months, and viremic
controllers (VCs), with VLs between 200 and 2000 copies per
milliliter. ECs and VCs have been extensively studied in the
developed world to determine underlying mechanisms responsible
for virologic control. In sub-Saharan Africa, most studies have
characterized LTNPs based on immunologic criteria making it
difﬁcult to compare ﬁndings with the Western cohorts, which use
virologic criteria. Here, we describe a cohort of Uganda ECs and
VCs attending a large HIV ambulatory center in Kampala,
Uganda, based initially on CD4 counts and conﬁrmed by repeated
VL measurements.
Methods: A cross-sectional study was conducted among 14,492
HIV-infected, antiretroviral therapy–naive individuals aged 18 years
and older under care for at least 5 years with serial peripheral CD4
counts $500 cells/mL. Among those, we determined the frequency
of individuals with VLs ,2000 copies per milliliter for at least
6 months.
Results: We report a prevalence of 0.26% (38/14,492) of HIV
controllers in the clinic. We identiﬁed 36 ECs and 2 VCs. These
individuals were middle-aged with an average CD4 count of 858 6
172 (mean 6 SD, 95% conﬁdence interval: 795 to 921). Their
average duration in HIV care was 7.46 2.1 years (mean 6 SD, 95%
conﬁdence interval: 6.6 to 8.1). The majority of EC/VCs were
women (87%, 33/38), reﬂecting the demographics of the
urban clinic.
Conclusions: For the ﬁrst time, this study demonstrates the
frequency of EC/VCs in a large urban clinic in Uganda. Further
study of these East African subjects may provide insights into how
some individuals are able to control HIV in the absence
of medications.
Key Words: HIV, elite controllers, viremic controllers, nonprog-
ressors, HIV cure, Uganda
(J Acquir Immune Deﬁc Syndr 2018;79:394–398)
INTRODUCTION
Before the availability of antiretroviral therapy (ART),
the median time from HIV seroconversion to AIDS-deﬁning
illness was 8–10 years.1,2 Without ART, in the majority of
HIV-infected individuals, seropositivity is associated with
an inevitable loss of CD4+ T cells, resulting in the
development of AIDS.3 In a few, rare individuals, however,
there is little or no clinical progression. These individuals
typically maintain elevated CD4+ T-cell counts. Based on
these immunological criteria, they are termed as long-term
nonprogressors (LTNPs).2 In the Western world, these
individuals comprise about 3%–5% of the HIV-infected
population.4 With recent developments in viral load (VL)
detection to levels as low as 20 copies per milliliter,5
researchers in the Western countries have reclassiﬁed
LTNPs based on virologic criteria.6 Two phenotypes have
been deﬁned: the ﬁrst includes individuals able to fully
suppress HIV-1 replication, with undetectable plasma VLs
(below 20–50 copies/mL) for at least 6–12 months; these are
referred to as elite controllers (ECs).6 The second includes
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individuals who have detectable plasma VLs ,2000 copies
per milliliter, referred to as viremic controllers (VCs).6
Mechanisms resulting in virologic control have not
been fully uncovered. For EC/VCs in the developed world,
approximately 20% of the phenotype can be explained by
protective HLA alleles7; other immune and host genetic
mechanisms may also be operational.8 However, there is
paucity of literature regarding adult LTNPs in sub-Saharan
Africa, and the prevalence of the phenotype is unknown,
mainly due to differences in deﬁnitions used.9 In sub-Saharan
Africa, most studies have characterized LTNPs based on
immunologic criteria, making it difﬁcult to compare ﬁndings
with the Western cohorts that use virologic criteria.6 Recent
data from Rakai HIV cohort in Uganda reported a prevalence
of 9.1% LTNPs and 1.4% ECs. Their deﬁnition of EC was
a one-time undetectable VL,9 and the prevalence of VCs was
not reported. Here, we characterize a cohort of adult HIV+
Ugandan ECs/VCs attending a large ambulatory clinic in
Kampala, Uganda. Further study of these East African
subjects may provide insights into how some individuals
are able to control HIV in the absence of ART.
METHODS
Study Design and Population
A cross-sectional study was conducted between August
2016 and February 2018 by reviewing the medical records of
HIV+, ART-naive individuals aged 18 years and older, who
were under care at Makerere University Joint AIDS Program
(MJAP), Mulago ISS clinic in Kampala, Uganda for at least 5
years. Patients were enrolled after a baseline or initial VL of
less than 2000 copies per milliliter, with serial CD4 counts $
500 cells/mL. An arbitrary zero time point corresponding to
FIGURE 1. Screening and enrollment flow chart for study participants.
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the initial VL was set for all participants. At recruitment,
peripheral blood sample was obtained and HIV VL was
analyzed by quantitative reverse transcriptase–polymerase
chain reaction using Abbott RealTime HIV-1 assay (Abbott
Molecular, Des Plaines, IL). The time interval between initial
and enrollment VL was determined and recorded in days. To
conﬁrm EC/VC status, a follow-up VL was performed and the
time interval between baseline and follow-up VL was also
calculated. For safety reasons, we excluded any individuals
with a hemoglobin of ,10 mg/dL, or active opportunistic
infection. Before November 2016, HIV-infected individuals
were started on ART when their CD4+ T-cell count dropped
below 500 cells/mL. Following the Test and Treat policy
launched by the Ugandan Ministry of Health on the
November 29, 2016, which was operational at the ISS clinic
beginning in March 2017, we excluded participants who were
started on ART, irrespective of CD4 count. Sociodemo-
graphic and clinical characteristics of the study participants
TABLE 1. Demographic and Clinical Characteristics of Participants
Participant Age Sex
Baseline
CD4 Count
Duration in
Care (yrs)
Baseline or Initial
Viral Load (Day 0)
Enrollment Viral Load (Days
From Initial Viral Load)
Follow-up Viral Load (Days
From Initial Viral Load) BMI*
EC 1 53 F 1245 10 UD UD (254) UD (593) 33.9
EC 2 40 M 920 6 UD 10,500 (151) UD (518) 27.2
EC 3 32 F 1008 5 UD UD (261) UD (368) 31.8
EC 4 38 F 919 9 UD UD (361) UD (754) 18.9
EC 5 51 F 895 10 UD 1300 (302) UD (368) 29.5
EC 6 38 F 1162 6 UD 75 (253) UD (350) 25.3
EC 7 36 F 1188 7 UD UD (250) UD (380) 38.5
EC 8 41 F 1192 6 UD 2840 (315) UD (360) 37.5
EC 9 40 F 940 5 UD 10,800 (125) 189 (580) 26.3
EC 10 37 F 805 5 UD 155 (458) UD (496) 24.5
EC 11 56 M 833 7 UD UD (274) Missing 17.2
EC 12 54 F 669 8 UD 782 (156) UD (372) 25.3
EC 13 42 F 909 5 UD UD (372) UD (647) 31.8
EC 14 30 F 1050 5 UD UD (304) UD (340) 29.3
EC 15 34 F 918 8 UD 1490 (104) UD (388) 24.2
EC 16 29 F 747 5 UD 14,800 (138) UD (392) Missing
EC 17 27 F 609 6 UD 209 (127) UD (374) 27.8
EC 18 37 F 728 6 UD UD (273) UD (366) 23.9
EC 19 39 F 650 9 UD UD (160) UD (436) Missing
EC 20 27 F 716 7 UD 97 (291) UD (402) 30.7
EC 21 32 F 698 5 UD 280 (409) UD (747) 30
EC 22 56 F 652 8 UD 1380 (228) UD (465) 25.3
EC 23 47 F 1322 9 UD UD (299) UD (388) 31.2
EC 24 38 F 589 5 UD 75,100 (301) UD (362) 21.4
EC 25 42 F 1120 10 UD UD (308) 160 (525) Missing
EC 26 42 F 1021 8 UD 5250 (180) UD (451) 21.3
EC 27 37 F 772 10 UD 243 (278) UD (584) 29
EC 28 35 F 1055 12 UD 12,500 (284) UD (388) 20.4
EC 29 40 F 994 10 UD UD (272) UD (366) 32.3
EC 30 41 M 778 9 UD UD (366) UD (434) 25.2
EC 31 37 F 1063 6 UD UD (252) UD (316) 26.1
EC 32 40 M 732 6 UD 388 (255) UD (393) 28.9
EC 33 38 F 719 6 UD 113 (248) UD (383) Missing
EC 34 45 F 1036 6 UD UD (325) UD (425) Missing
EC 35 42 F 836 6 UD 99 (286) UD (362) 35.5
EC 36 28 F 653 8 UD UD (279) UD (370) Missing
VC 1 41 F 852 10 UD 285 (221) Missing 30.2
VC 2 56 M 897 11 UD 1220 (429) Missing 25.6
Progressor
1
43 F 781 8 UD 2310 (137) 10,200 (394) 32.7
Progressor
2
37 F 631 11 UD 10,200 (426) Missing 27.4
*BMI, body mass index; EC, elite controller; UD, Undetectable; VC, viremic controller.
Kayongo et al J Acquir Immune Defic Syndr  Volume 79, Number 3, November 1, 2018
396 | www.jaids.com Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
were obtained from electronic medical records. The partic-
ipants agreed and signed informed consent forms to take part
in the study. The research was approved by School of
Biomedical Sciences, Higher Degrees Research and Ethics
committee (SBS HDREC), Makerere University, and the
National Council of Science and Technology (UNCST).
Statistical Analysis
Analysis was performed using GraphPad Prism version
7.0. Continuous variables were summarized using mean
values and SDs or medians and interquartile range [conﬁ-
dence interval (CI)]. The frequencies of ECs and VCs were
expressed as percentages of the total population analyzed. P
values ,0.05 were consider signiﬁcant.
RESULTS
The medical records of 14,492 HIV+ individuals
followed in the ISS clinic were reviewed (Fig. 1). Of those,
335 were ART-naive, followed for more than 5 years, with
multiple CD4 counts not less than 500/mL. Approximately 2/
3rds of those (232/335) had begun on ART before recruitment
and were thus excluded from further study. Of the remaining
103, 3 had no baseline or initial VL and 57 had VL .2000.
Forty-three subjects thus had an initial VL performed, which
in all cases was undetectable, and of those, 2 refused consent
for the study. Forty of 41 consented participants had an
enrollment VL. Out of those 40 subjects, 9 had enrollment VL
.2000, and 31 had VL ,2000. At follow-up VL testing, 36
had VL ,2000, 1 had VL .2000, and 3 were missing
a follow-up VL. Based on the 3 serial VLs, 36 were classiﬁed
FIGURE 2. Select characteristics of study participants. Comparison of demographic and clinical characteristics of ECs, VCs, and
progressors. A, baseline CD4 counts, (B) serial CD4 counts, (C) age, (D) BMI, and (E) systolic blood pressure or SBP. Data were
analyzed for each variable using the Mann–Whitney test. Shown are mean and SD for B; medians, 25th and 75th percentiles, and
range for other figures, n.s., not significant or P . 0.05.
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as ECs, 2 as VCs, and 2 as progressors (Table 1).
Demographic and clinical characteristics of those patients
are shown in Table 1. These subjects had a mean age of 40.8
6 8.2 years (mean 6 SD, 95% CI: 37.5 to 43.5) and an
average CD4 count of 858 6 172 (mean 6 SD, 95% CI: 795
to 921). Their average duration in HIV care was 7.4 6 2.1
years (mean 6 SD, 95% CI: 6.6 to 8.1), and 87% (27/31)
were women. The female predominance reﬂects the sex
disparity of the ISS clinic. None, including those deﬁned as
progressors, developed any AIDS-deﬁning illness during the
course of the study.
In comparing ECs, VCs, and progressors, there were no
differences in peripheral CD4 T-cell counts (P value = ns,
Fig. 2A). There was also no signiﬁcant difference in the
trends of CD4 count over a 5-year period between those
groups, suggesting that CD4 count alone is not a distinguish-
ing feature of controller status (Fig. 2B). In addition, there
was no difference in average age between EC/VC and
progressors (40.29 6 8.48 vs. 38.6 6 4.142, Fig. 2C), in
body mass indices, or systolic blood pressure measurements
(Figs. 2D, E). In reviewing the medical records of these EC/
VCs, we found no history of tuberculosis, other opportunistic
infections, or any AIDS-deﬁning illnesses. Similarly, the
progressors did not have a history of any AIDS-deﬁning
illnesses. Thus, for those individuals who maintained high
CD4 counts over time, there were no distinguishing demo-
graphic or clinical features to predict whether they were EC/
VC or would become progressors, at least for the relatively
short duration of this study. We uncovered no evidence that
any of these EC/VCs were ever prescribed or took any ART.
DISCUSSION
This is the ﬁrst study in Uganda to characterize HIV+
LTNP in 2 subsets, that is, ECs and VCs, based on virologic
criteria. In most studies demonstrating the existence of ECs
and VCs in sub-Saharan Africa, the cohorts have been very
small, solely based on immunologic criteria, and viral and
host genetics have not been explored.9,10 Due to differences
in deﬁnitions of HIV long-term nonprogression, the preva-
lence and clinical characteristics of HIV controllers who have
not received ART is largely undeﬁned.6,9 In contrast to a high
frequency of HIV controllers reported based on immunologic
criteria by Laeyendecker et al9 in 2009 (9.1%), we demon-
strate a lower prevalence of HIV EC/VCs based on VL
(0.26%). This is probably an underestimate due to a variety of
reasons, including (1) it is likely that a number of EC/VCs
with a peripheral CD4 ,500/mL had already been initiated on
ART and thus excluded from the study, and (2) the newly
launched Test and Treat policy in Uganda in which the
majority (here, 69%) of potential HIV controllers with CD4
.500 had already been started on ART and were thus
automatically excluded from our study. Thus, we would
estimate that the true frequency of EC + VCs in this clinic is
greater than 1 in 500 patients.
In addition, it has been shown that healthy HIV-
negative Africans have lower CD4 counts compared with
those of US and other Western patients, suggesting that strict
immunologic criteria may not be fully generalizable or
applicable to African populations.9 Because many EC/VCs
in the developed world have CD4 counts ,500, setting
a threshold CD4 count .500 would have excluded perhaps
even a greater number of Ugandan HIV controllers. One
concern is that the Test and Treat strategy recommended by
the World Health Organization and now being implemented
throughout Africa will preclude the in-depth mechanistic
study of EC/VCs, who represent functional cures of HIV.
Whether more widespread VL testing will temper the World
Health Organization Test and Treat policy, coupled with fears
regarding limited resources and growing expenses of ART,
not to mention increasing virus resistance by giving ART in
the absence of VL measurements, remains to be seen.
CONCLUSIONS AND RECOMMENDATIONS
This study demonstrates the existence of HIV+ EC/VCs
in Uganda based on very strict, conservative criteria and
highlights the importance of deﬁning control of HIV based on
VL testing in the developing world. It is hoped that these
individuals, as models for functional cure, will help us
understand the underlying mechanisms of HIV control in
East Africans, which may differ from those in the Western
world, including African Americans, whose origins are
mainly West African. Further study of Ugandan EC/VCs
may inform both the cure agenda and prophylactic
vaccine efforts.
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